Phase Ib/II Study of Enzalutamide With Decitabine, a DNA Hypomethylating Agent, in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 20 Dec 2018
At a glance
- Drugs Decitabine (Primary) ; Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Dec 2018 Planned initiation date changed from 30 Nov 2018 to 30 Jan 2019.
- 12 Nov 2018 Planned initiation date changed from 1 Nov 2018 to 30 Nov 2018.
- 25 Oct 2018 New trial record